Efficacy and safety of tocilizumab in treatment of Takayasu arteritis: A systematic review of randomized controlled trials

References

• Arnaud L, Kahn J-E, Girszyn N, Piette A-M, Bletry O. Takayasu’s arteritis: an update on physiopathology. Eur J Intern Med. 2006;17(4):241–6.
   PubMed Web of Science ®Google Scholar
• Klippel JH, Stone JH, White PH. Primer on the rheumatic diseases. New York: Springer Science & Business Media; 2008.
   Google Scholar
• Onen F, Akkoc N. Epidemiology of Takayasu arteritis. Presse Med. 2017;46(7–8):e197–e203.
   PubMed Web of Science ®Google Scholar
• Kerr GS, Hallahan CW, Giordano J, Leavitt RY, Fauci AS, Rottem M, et al. Takayasu arteritis. Ann Intern Med. 1994;120(11):919–29.
   PubMed Web of Science ®Google Scholar
• Abularrage CJ, Slidell MB, Sidawy AN, Kreishman P, Amdur RL, Arora S. Quality of life of patients with Takayasu’s arteritis. J Vasc Surg. 2008;47(1):131–7.
   PubMed Web of Science ®Google Scholar
• Omma A, Erer B, Karadag O, Yilmaz N, Alibaz-Oner F, Yildiz F, et al. Remarkable damage along with poor quality of life in Takayasu arteritis: cross-sectional results of a long-term followed-up multicentre cohort. Clin Exp Rheumatol. 2017;103(35 Suppl 1):77–82.
   PubMed Web of Science ®Google Scholar
• Yilmaz N, Can M, Oner FA, Kalfa M, Emmungil H, Karadag O, et al. Impaired quality of life, disability and mental health in Takayasu’s arteritis. Rheumatology.2013;52(10):1898–904.
   PubMed Web of Science ®Google Scholar
• Hoffman GS, Leavitt RY, Kerr GS, Rottem M, Sneller MC, Fauci AS. Treatment of glucocorticoid‐resistant or relapsing Takayasu arteritis with methotrexate. Arthritis Rheum.1994;37:578–82.
   PubMed Web of Science ®Google Scholar
• Erbel R, Aboyans V, Boileau C, Bossone E, Bartolomeo RD, Eggebrecht H, et al. 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases: Document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC). Eur Heart J. 2014;35:2873–926.
   PubMed Web of Science ®Google Scholar
• Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis. 2009;68:310–7.
   PubMed Web of Science ®Google Scholar
• NHS England. (2019). Clinical Commissioning Policy Proposition: Tocilizumab for Takayasu arteritis (adults). [online] Available at: https://www.engage.england.nhs.uk/consultation/clinical-commissioning-wave8/user_uploads/a13x06-policy-prop.pdf [last accessed 7 Oct 2019].
   Google Scholar
• Maksimowicz-McKinnon K, Clark TM, Hoffman GS. Limitations of therapy and a guarded prognosis in an American cohort of Takayasu arteritis patients. Arthritis Rheum. 2007;56(3):1000–9.
   PubMed Web of Science ®Google Scholar
• Dai D, Wang Y, Jin H, Mao Y, Sun H. The efficacy of mycophenolate mofetil in treating Takayasu arteritis: a systematic review and meta-analysis. Rheumatol Int. 2017;37(7):1083–8.
   PubMed Web of Science ®Google Scholar
• Tombetti E, Di Chio MC, Sartorelli S, Bozzolo E, Sabbadini MG, Manfredi AA, et al. Anti-cytokine treatment for Takayasu arteritis: state of the art. Intractable Rare Dis Res. 2014;3(1):29–33.
   Google Scholar
• Clifford A, Hoffman GS. Recent advances in the medical management of Takayasu arteritis: an update on use of biologic therapies. Curr Opin Rheumatol. 2014;26(1):7–15.
   PubMed Web of Science ®Google Scholar
• Weyand CM, Goronzy JJ. Medium-and large-vessel vasculitis. N Engl J Med. 2003;349(2):160–9.
   PubMed Web of Science ®Google Scholar
• Saadoun D, Garrido M, Comarmond C, Desbois AC, Domont F, Savey L, et al. Th1 and Th17 cytokines drive inflammation in Takayasu arteritis. Arthritis Rheumatol. 2015;67(5):1353–60.
   Web of Science ®Google Scholar
• Kong X, Sun Y, Ma L, Chen H, Wei L, Wu W, et al. The critical role of IL-6 in the pathogenesis of Takayasu arteritis. Clin Exp Rheumatol. 2016;34(3 Suppl 97):S21–S7.
   PubMed Web of Science ®Google Scholar
• Manel N, Unutmaz D, Littman DR. The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat. Nat Immunol. 2008;9(6):641–9.
   PubMed Web of Science ®Google Scholar
• Kong X, Ma L, Ji Z, Dong Z, Zhang Z, Hou J, et al. Pro-fibrotic effect of IL-6 via aortic adventitial fibroblasts indicates IL-6 as a treatment target in Takayasu arteritis. Clin Exp Rheumatol. 2018;36(1):62–72.
   PubMed Web of Science ®Google Scholar
• Abisror N, Mekinian A, Lavigne C, Vandenhende M-A, Soussan M, Fain O. Tocilizumab in refractory Takayasu arteritis: a case series and updated literature review. Autoimmun Rev. 2013;12(12):1143–9.
   PubMed Web of Science ®Google Scholar
• Nakaoka Y, Higuchi K, Arita Y, Otsuki M, Yamamoto K, Hashimoto-Kataoka T, et al. Tocilizumab for the treatment of patients with refractory Takayasu arteritis. Int Heart J. 2013;54(6):405–11.
   PubMed Web of Science ®Google Scholar
• Osman M, Emery D, Yacyshyn E. Tocilizumab for treating Takayasu’s Arteritis and associated stroke: a case series and updated review of the literature. J Stroke Cerebrovasc Dis. 2015;24(6):1291–8.
   PubMed Web of Science ®Google Scholar
• Goel R, Danda D, Joseph G, Ravindran R, Kumar S, Jayaseelan V, et al. Long-term outcome of 251 patients with Takayasu arteritis on combination immunosuppressant therapy: single centre experience from a large tertiary care teaching hospital in Southern India. Semin Arthrit Rheum. 2018;47(5):718–26.
   PubMed Web of Science ®Google Scholar
• Evans J, Steel L, Borg F, Dasgupta B. Long-term efficacy and safety of tocilizumab in giant cell arteritis and large vessel vasculitis. RMD Open.2016;2(1):e000137.
   PubMed Web of Science ®Google Scholar
• Keser G, Direskeneli H, Aksu K. Management of Takayasu arteritis: a systematic review. Rheumatology 2014;53(5):793–801.
   PubMed Web of Science ®Google Scholar
• Loricera J, Blanco R, Hernández JL, Castañeda S, Humbría A, Ortego N, et al. Tocilizumab in patients with Takayasu arteritis: a retrospective study and literature review. Clin Exp Rheumatol 2016;34(3 Suppl 97):S44–S53.
   PubMed Web of Science ®Google Scholar
• Osman M, Pagnoux C, Dryden DM, Storie D, Yacyshyn E. The role of biological agents in the management of large vessel vasculitis (LVV): a systematic review and meta-analysis. PLoS One.2014;9(12):e115026.
   PubMed Web of Science ®Google Scholar
• Unizony S, Arias ‐Urdaneta L, Miloslavsky E, Arvikar S, Khosroshahi A, Keroack B, et al. Tocilizumab for the treatment of large‐vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica. Arthritis Care Res (Hoboken). 2012;64(11):1720–9.
   Web of Science ®Google Scholar
• Zhou J, Chen Z, Li J, Yang Y, Zhao J, Chen H, et al. The efficacy of tocilizumab for the treatment of Chinese Takayasu’s arteritis. Clin Exp Rheumatol. 2017;103(35 Suppl 1):171–5
   Web of Science ®Google Scholar
• Singh A, Hussain S, Najmi AK, Efficacy and safety of tocilizumab in treatment of Takayasu arteritis: protocol for a systematic review of randomized controlled trials. Available from: https://www.crd.york.ac.uk/prospero/display_record.asp?ID=CRD42017064542.
   Google Scholar
• Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1.
   PubMed Web of Science ®Google Scholar
• Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, et al. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet.2008;371(9609):281–3.
   PubMed Web of Science ®Google Scholar
• Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMC Med. 2010;8(1):18.
   PubMed Web of Science ®Google Scholar
• Review Manager (RevMan) [Computer program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration; 2014.
   Google Scholar
• Nakaoka Y, Isobe M, Takei S, Tanaka Y, Ishii T, Yokota S, et al. Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomized, double-blind, placebo-controlled, phase 3 trial in Japan [abstract]. Arthritis Rheumatol. 2016;68(suppl 10).
   Google Scholar
• Nakaoka Y, Isobe M, Takei S, Tanaka Y, Ishii T, Yokota S, et al. Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study). Ann Rheum Dis. 2018;77(3):348–54.
   PubMed Web of Science ®Google Scholar
• Singh A, Hussain S, Najmi AK. Number of studies, heterogeneity, generalisability, and the choice of method for meta-analysis. J Neurol Sci. 2017;381:347.
   PubMed Web of Science ®Google Scholar
• Hussain S, Singh A, Rahman SO, Habib A, Najmi AK. Calcium channel blocker use reduces incident dementia risk in elderly hypertensive patients: a meta-analysis of prospective studies. Neurosci Lett. 2018;671:120–7.
   PubMed Web of Science ®Google Scholar
• Singh A, Hussain S, Najmi AK, Lakhan SE. Efficacy and safety of tocilizumab in treatment of Takayasu arteritis: a systematic review of randomized controlled trials. Atheroscler Suppl. 2018;32:121–2.
   Web of Science ®Google Scholar
• Hussain S, Singh A, Akhtar M, Najmi AK. Vitamin D supplementation for the management of knee osteoarthritis: a systematic review of randomized controlled trials. Rheumatol Int. 2017;37(9):1489–98.
   PubMed Web of Science ®Google Scholar
• Koike T, Harigai M, Inokuma S, et al. Effectiveness and safety of tocilizumab: postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan. J Rheumatol. 2014;41:15–23.
   PubMed Web of Science ®Google Scholar
• Batu ED, Sönmez HE, Hazırolan T, Özaltın F, Bilginer Y, Özen S. Tocilizumab treatment in childhood Takayasu arteritis: case series of four patients and systematic review of the literature. Semin Arthritis Rheum. 2017;46(4):529–35.
   PubMed Web of Science ®Google Scholar
• Cañas CA, Cañas F, Izquierdo JH, et al. Efficacy and safety of anti–interleukin 6 receptor monoclonal antibody (tocilizumab) in Colombian patients with Takayasu arteritis. JCR: J Clin Rheumatol. 2014;20:125–9.
   PubMed Web of Science ®Google Scholar
• Goel R, Danda D, Kumar S, Joseph G. Rapid control of disease activity by tocilizumab in 10 ‘difficult-to-treat’ cases of Takayasu arteritis. Int J Rheum Dis. 2013;16(6):754–61.
   PubMed Web of Science ®Google Scholar
• Mekinian A, Resche-Rigon M, Comarmond C, Soriano A, Constans J, Alric L, et al. Efficacy of tocilizumab in Takayasu arteritis: multicenter retrospective study of 46 patients. J Autoimmun. 2018;91:55–60.
   PubMed Web of Science ®Google Scholar
• Salvarani C, Magnani L, Catanoso MG, Pipitone N, Versari A, Dardani L, et al. Case report: rescue treatment with Tocilizumab for Takayasu arteritis resistant to TNF-α blockers. Clin Exp Rheumatol 2012;30(1 Suppl 70):S90–S3.
   PubMed Web of Science ®Google Scholar
• Seitz M, Reichenbach S, Bonel HM, Adler S, Wermelinger F, Villiger P. Rapid induction of remission in large vessel vasculitis by IL-6 blockade. A case series. Swiss Med Wkly. 2011;141:w13156.
   PubMed Web of Science ®Google Scholar
• Tombetti E, Franchini S, Papa M, Sabbadini MG, Baldissera E. Treatment of refractory Takayasu arteritis with tocilizumab: 7 Italian patients from a single referral center. J Rheumatol. 2013;40:2047–51.
   PubMed Web of Science ®Google Scholar
• Decker P, Olivier P, Risse J, Zuily S, Wahl D. Tocilizumab and refractory Takayasu disease: rour case reports and systematic review. Autoimmun Rev. 2018;17(4):353–60.
   PubMed Web of Science ®Google Scholar